Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
about
Clinical use of HIV integrase inhibitors: a systematic review and meta-analysisFidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programmeConsiderations for Endpoint Selection When Designing HIV Clinical Trials.Composite endpoints in trials of type-2 diabetes.Clinical trials and systematic reviews addressing similar interventions for the same condition do not consider similar outcomes to be important: a case study in HIV/AIDS.Methodological challenges in the use of hip-specific composite outcomes: linking measurements from hip fracture trials to the International Classification of Functioning, Disability and Health Framework.An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring.Beyond Composite Endpoints Analysis: Semicompeting Risks as an Underutilized Framework for Cancer Research.Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.
P2860
Q28484930-EAF79F7E-A95A-485D-A619-7A90E8BFFADBQ30425705-B3F305C9-9E05-4BFD-8227-B74DBD3B3456Q31105054-2DDE39EE-A809-4F4F-93AF-56FFEB985FF8Q33782194-0F0FD5E3-C005-4C4D-B475-A97CCF2131CCQ37334002-321D94FC-D084-49B8-B761-C086C1484A81Q37967498-D8368AC1-B855-4316-B806-5FD45AD030A5Q38154679-FD017635-CBB8-4DB1-AC61-38AC847D9428Q38935225-2EDC00DA-2A0E-465E-A017-422A9CF957EBQ39369042-125955BB-B7C8-4DCF-9DA3-FFC973B7725AQ39528631-77365F51-FF7B-4024-9742-7F82A1ABBC35Q39628955-32C6B546-339F-4ED2-93AD-6E5858BC839AQ47180993-38C488F4-178D-4616-A1CD-928145446BEEQ51066498-E36008F9-54F5-43A0-A163-CFF1CC098F52
P2860
Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methodological issues in the u ...... : examples from the HIV field.
@en
Methodological issues in the u ...... : examples from the HIV field.
@nl
type
label
Methodological issues in the u ...... : examples from the HIV field.
@en
Methodological issues in the u ...... : examples from the HIV field.
@nl
prefLabel
Methodological issues in the u ...... : examples from the HIV field.
@en
Methodological issues in the u ...... : examples from the HIV field.
@nl
P2093
P2860
P50
P356
P1433
P1476
Methodological issues in the u ...... : examples from the HIV field.
@en
P2093
Abdel Babiker
Andrew Phillips
Colette Smith
Genevieve Chêne
Jean-Pierre Aboulker
Laura Richert
P2860
P356
10.1177/1740774509356117
P577
2010-02-01T00:00:00Z